

**Crossing the oxidative DNA
damage threshold - consequences
resulting from the loss of the
NEIL1 DNA glycosylase**

R. Stephen Lloyd

**Center for Research on Occupational and
Environmental Toxicology and
Department of Molecular & Medical Genetics
Oregon Health & Science University**

DNA Repair & Related Transactions



October 2001

Erling Seeberg
Arthur Grollman
Stephen Lloyd

But.....we were not alone

Sankar Mitra	3/2002	(NEH1)
Susan Wallace	4/2002	(NEIL1)
Mitra, Hazra, Izumi	7/2002	(NEIL2)
Erling Seeberg	9/2002	(HFPG1)
Akira Yasui	9/2002	(NEIL1)
Arthur Grollman	1/2003	(NEIL1)

Reaction Mechanism of DNA Glycosylase/AP Lyases




Catalytic Mechanism

Glycosylase/ β , δ elimination catalyst


Higher catalytic efficiency on single-stranded vs double-stranded DNA and S-phase expression \Rightarrow replication-associated and/or transcription-coupled repair (Dou et al, 2003)

Stimulated by the hus1, Rad1, Rad9 (9-1-1 complex)


Major Products of Oxidative Damage to DNA Bases




5-hydroxy-6-hydroxythymine




thymine glycol




5,6-dihydrothymine




5-hydroxymethyluracil




5-formyluracil




5-hydroxy-5-methylhydantoin




cytosine glycol




5-hydroxycytosine




5,6-dihydroxycytosine




5-hydroxy-6-hydroxycytosine




trans-1-carbamoyl-2-oxo-4,5-dihydroimidazolidine




uracil glycol




5-hydroxyuracil




5,6-dihydroxyuracil




5-hydroxy-6-hydroxyuracil




5-hydroxyhydantoin




alloxan




5,6-dihydrouracil




8-hydroxyadenine




4,6-diamino-5-formamidopyrimidine




2-hydroxyadenine



8-hydroxyguanine



2,6-diamino-4-hydroxy-5-formamidopyrimidine



oxazolone

* = Lack of recognition redundancy for:
FapyA, 5S,6R TG, SP, GH

May suggest a critical role for NEIL1 in
maintenance of genomic integrity

Radiation Sensitivity of *neil1* si RNA Depleted Cells





Fig. 5. Radiation survival curves for control embryonic stem cells containing the empty vector pH1P-neo or three clones containing the *Neil1*-hairpin expression plasmid, pNEIL1HP.

Rosenquist et al.
2003

Glycosylase Knockout Mice

KOs made in *ung*, *mpg*, *ogg1*, *nth*,
mutY etc with essentially no
phenotype until combined with
other BER or p53 mutants

neil1^{-/-} Male with Control WT Age-matched Male



General Phenotype

- Manifests predominantly in males; mild to no phenotype in females
- Mice fed low fat (10% caloric intake fat)
- No exogenous oxidative stressors
- Chow consumption indistinguishable between *neil1* KO and WT
- Majority of male KO show late onset obesity

Paternal Inheritance

(S. Ballinger, UAB)


- Extensive colony of *neil1* KO that reveal a strong paternal inheritance of final steady-state weight
- However, DEXA analyses reveal same % body fat content

WT = 15-18%; KO (~40g) = 36% fat; KO (~50g) = 39% fat


Fat Deposition in Abdomen of *neil1*^{-/-}




Fat Deposition in Abdomen of *neil1*^{-/-}






Age-dependent Increase in Leptin Values in *neil1*^{-/-}




Fatty Liver Disease in *neil1*^{-/-} Mice




Fatty Liver Disease in *neil1*^{-/-}




KO male (12 month) hepatic necrosis



**KO male (16 month)
hepatic fibrotic sclerosis**



KO female liver



Plasma Lipids

	WT	KO
Triglycerides (TG)	230 ng/ μ l	440 ng/ μ l
Free fatty Acids (FFA)	21 ng/ μ l	51 ng/ μ l
Cholesterol Esters (CE)	332 ng/ μ l	445 ng/ μ l


Anti-inflammatory Fatty Acids

DHA docosahexaenoic acid (22:6)


EPA eicosapentaenoic acid (20:5)

	<u>WT</u>	<u>KO</u>
DHA in TG	11 ng/ μ l	25 ng/ μ l
EPA in TG	4.9	9.0
DHA in FFA	0.6	2.3
EPA in FFA	0.3	0.7
DHA in CE	14	30
EPA in CE	10	20
Total DHA	25.6	57.3
Total EPA	15.2	29.7


**KO male kidney: aqueous vacuolization
consistent with type II diabetes**




KO male (12 months) hypertrophy of Bowman's capsule




KO male (12 months) membranous glomerulopathy





Age-dependent Increase in Insulin Values in *neil1*^{-/-}



KO male (12 months) pancreas



Relationship of triglycerides and insulin levels in the wild-type and *neil1*^{-/-} mice





Metabolic Syndrome Phenotype

- √ Severe obesity
- √ Fatty liver disease
- √ Insulin resistance
- √ Dyslipidemia
- x Hypertension



Constellation of Diseases:

Also observed in heterozygotic mice, but later in life
Cancer proneness: late onset, affecting liver and epidermal tissues







mtDNA Damage in *neil1*^{-/-}



Mitochondrial Deletions (males)



Overweight



Severely
Overweight



Controls

How could the loss of a DNA repair glycosylase lead to this constellation of diseases?


Current Hypothesis

**NEIL1 deficiency lowers the threshold
at which cumulative oxidative stress-induced
DNA damage
destabilizes metabolic homeostasis**

Heterozygotes develop same
phenotype but at a slower rate


Potential implications for human health

NEIL1 Crystal Structure




PDB: 1TDH
Doublie et al, 2004


Location of Polymorphic Variants of NEIL1




PDB: 1TDH
Doublet et al, 2004



Survey of Abasic Site Lyase Activities of NEIL1 Variants




Kinetics of Abasic Site Lyase Activities




TG in Duplex

TG in Bubble



NEIL1 Enzymatic Activity



Kinetic constants for excision of FapyAde and FapyGua by human wild-type NEIL1, D252N-NEIL1 and S82C-NEIL1 from DNA γ -irradiated in aqueous buffered solution saturated with N₂O

Substrate	V_{\max} (nM min ⁻¹)	k_{cat} (min ⁻¹)	K_M (nM)	$k_{\text{cat}}/K_M \times 10^5$ (min ⁻¹ nM ⁻¹)
<u>Wild type NEIL1</u>				
FapyAde	5.17 ± 0.58 ^a	0.0114 ± 0.0020	2420 ± 284	0.470 ± 0.104
FapyGua	3.79 ± 0.45	0.0083 ± 0.0018	3572 ± 469	0.233 ± 0.052
<u>D252N-NEIL1</u>				
FapyAde	3.34 ± 0.51	0.0074 ± 0.0021	1677 ± 277	0.438 ± 0.130
FapyGua	3.17 ± 0.38	0.0070 ± 0.0016	3493 ± 466	0.200 ± 0.045
<u>S82C-NEIL1</u>				
FapyAde	3.04 ± 0.65	0.0067 ± 0.0030	1378 ± 308	0.485 ± 0.020
FapyGua	3.73 ± 1.01	0.0082 ± 0.0417	6841 ± 1817	0.127 ± 0.064

^aValues represent the mean ± standard deviation ($n = 6$). $k_{\text{cat}} = V_{\max}/[\text{enzyme}]$. The enzyme concentration was 454 nM. Concentration ranges of FapyAde and FapyGua were 0.32 μM –4.29 μM and 0.92 μM –8.69 μM , respectively.

Human Polymorphic Variants of *neil1*

Residue #	Frequency*	Activity
S82C	1.1 %	Wild type
G83D	1.1 %	No glycosylase
R136C	1.1 %	No glycosylase
I182M	0.5%	?
D252N	2.4%	Wild type

* NCBI SNP database

Hypothesis:

Humans carrying inactive polymorphic variants in NEIL1 will be at greater risk of developing the Metabolic Syndrome.


Goal:

Screen normal human controls and Metabolic Syndrome patients for variants in NEIL1.

Ongoing Collaborative Investigations:

Large scale sequencing of Hertfordshire Metabolic Syndrome Cohort (>10,000)

Could KO of *neil1* affect gene expression in local vicinity and produce phenotype?



- IL18 KO mice: hyperphagic, obese, insulin^R
- Cyp19a1 KO mice: increased gonadal fat
- Lsm16 KO mice: reduced body fat
- Adip5: increases gonadal fat
- LipC alleles: increased obesity

- None match *neil1* KO phenotype
- Gene chip analyses – no significant changes of genes in the region

Metabolic Syndrome & Ataxia

Telangiectasia

(Schneider et al, 2006)

AT children

Cerebellar ataxia, skin and eye telangiectasia,
malignancies, immune deficiencies

Insulin resistance *

Metabolic Syndrome & AT

ApoE ^{-/-} background ATM ^{-/-}, ATM ^{+/-}, ATM ^{-/-}
fed Western diet 40% fat calories
absolute weight unchanged
% body fat 23% ^{+/+}; 33% ^{+/-}; 36% ^{-/-}
systolic & diastolic BP increases in ^{+/-}, ^{-/-}
cholesterol, TG, FFA unchanged
atherosclerosis very elevated in ^{+/-}, ^{-/-}

	Apo E ^{-/-} ATM ^{-/-}	NEIL1 ^{-/-}
weight	Unaffected	Increased
% fat	Increased	Increased
BP	Increased	ND
Cholesterol/TG/ FFA	Unaffected	Increased
Atherosclerosis	Severe	none

Acknowledgements



Vladimir Vartanian
Brian Lowell
Irina Minko
Laura Roy

Amanda McCullough, OHSU
Chris Corless, OHSU
Donald Houghton, OHSU
Dennis Koop, OHSU

Scott Ballinger, UAB
Tom Wood, UTMB
Jeff Ceci, UTMB
Irena King, UW
Miral Dizdaroglu, NIST
Jaruga Pawel

Supported by DK075974

USGS June 29, 2005

Location: human 15q25
mouse 9a5,3

Tissue distribution in human
liver
pancreas
thymus

S-phase specific expression in tissue culture
Up-regulated following oxidative stress

Hazra et al , 2003

Das et al, 2003

Morland et al, 2002

Intracellular Distribution

nucleolus

nucleus

mitochondria

Association with Rad9-Rad1-hus1 9-1-1
checkpoint sensor (Guan et al, 2007)